#USA #Class Action #San Francisco #Gossamer Bio #PROSERA Trial

Gossamer Bio Faces Class Action Lawsuit

Gossamer Bio, Inc. (NASDAQ: GOSS) is currently under siege as a class action lawsuit has been initiated against it, targeting both the company and its executives. The lawsuit is aimed at investors who purchased Gossamer securities between June 16, 2025, and February 20, 2026, during a tumultuous period marked by the announcement of disappointing trial results.

On February 23, 2026, Gossamer made a shocking disclosure that the results from its Phase 3 study for seralutinib, aimed at treating pulmonary arterial hypertension (PAH), failed to meet the primary endpoint. According to the trial's design, this primary endpoint was the change from baseline in the six-minute-walk distance at the 24-week mark. Following this announcement, shares of Gossamer plummeted by an astounding 80%, significantly impacting many investors.

In light of this drastic decline, Hagens Berman Sobol Shapiro LLP, a well-known national shareholder rights law firm, quickly mobilized an investigation into Gossamer's prior disclosures regarding the Phase 3 PROSERA study. They argue that Gossamer may have misled investors about the trial's design and outcomes, questioning the integrity of the company's recruitment protocols and monitoring processes.

For investors, the implications are severe. According to statements from the firm, Gossamer purportedly led them to believe that the trial would yield favorable results, banking on the past successes of similar studies in the industry. Management had pointed to the highly-lauded Merck Phase 3 STELLAR study of a rival drug, sotatercept, touting comparable efficacy in Latin America, where they had directed a significant portion of patient recruitment.

However, legal representation claims that Gossamer was reportedly aware of significant issues related to its trial design and results but chose to maintain a positive narrative to buoy investor sentiment. They allege that the company failed to disclose the high placebo response observed in Latin American participants, which unduly affected the overall outcomes of the PROSERA trial.

The aftermath of the February 23 announcement led to heightened scrutiny from the market and uncovered substantial concerns related to Gossamer’s operations. The massive stock price drop not only raised alarms about potential securities law violations but also drew attention to the company's failure to maintain the required minimum share price for continued trading on the Nasdaq.

Adding to the mounting pressures, Gossamer must now grapple with the repercussions of the lawsuit, with legal representatives urging investors who suffered losses to come forward. As of June 1, 2026, the firm is seeking to establish lead plaintiffs among the investors affected during the Class Period. They encourage anyone with insights or information relevant to the case to reach out, especially if they believe they possess non-public information about Gossamer Bio.

As Gossamer battles these allegations, its commitment to investor accountability will be tested, highlighting an increasingly scrutinized relationship between biotech firms and their investors. The legal proceedings could set important precedents regarding the responsibilities of pharma companies to transparently communicate trial results, especially when they do not align with optimistic projections.

With the investigation launched, Gossamer must navigate the turbulent waters of public scrutiny while striving to restore trust among its investor base. Should the plaintiffs succeed in proving that Gossamer misrepresented trial data and outcomes, the implications could be profound not only for the company but also for the broader biotech sector, where transparency and accountability are paramount.

For investors, the unfolding situation serves as a stark reminder of the risks associated with biotech investments and the critical need for due diligence, especially in light of potentially misleading corporate communications. As this story progresses, all eyes will be on how Gossamer Bio responds not only to this lawsuit but also to the ongoing expectations of its stakeholders.